BIIB Q4 2019 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.7B+4.1% YoY

Gross Profit

$3.2B87.8% margin

Operating Income

$1.8B48.4% margin

Net Income

$1.4B39.2% margin

EPS (Diluted)

$8.08

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

$2.0B

Free Cash Flow

$1.8B

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$27.2B

Total Liabilities

$13.9B

Stockholders' Equity

$13.3B

Cash & Equivalents

$2.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.5B	+4.1%
Gross Profit	$3.2B	$3.0B	+6.1%
Operating Income	$1.8B	$1.4B	+23.2%
Net Income	$1.4B	$947M	+52.1%

Revenue Segments

Product

$2.9B80%

Revenues from anti-cd20 therapeutic programs

$601M16%

Product and Service, Other

$146M4%

Geographic Segments

UNITED STATES

$1.8B60%

Non-US

$1.2B40%